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Introduction: We describe the case of a man who died of an abdominal aortic aneurysm rupture after an
intravitreal injection of bevacizumab for neovascular age-related macular degeneration.
Case presentation: A 74-year-old Korean man presented with visual disturbance in his right eye. He had previously
been diagnosed with diabetes and hypertension, which were controlled with oral medications. We diagnosed him
with neovascular age-related macular degeneration and he was treated by monthly intravitreal injection of bevacizumab
for three months. Four days after his third intravitreal bevacizumab injection, he died of an abdominal aortic aneurysm
rupture and uncontrolled bleeding.
Conclusion: Abdominal aortic aneurysm rupture is highly lethal and there is a possible correlation with intravitreal
injection of bevacizumab. Thus, we need to consider the risks of intravitreal bevacizumab injections for patients with
abdominal aortic aneurysms.
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Bevacizumab is a humanized recombinant monoclonal
immunoglobulin G antibody that binds and inhibits all
vascular endothelial growth factor (VEGF) isoforms. It
has been used for the treatment of neovascular age-
related macular degeneration (AMD), but was approved
by the US Food and Drug Administration as an adjuvant
agent in the treatment of metastatic colorectal carcin-
oma, not for neovascular AMD.
In chemotherapy regimens, bevacizumab is associated
with an increased risk of thromboembolic events [1]; the
systemic safety of an intravitreal injection of bevacizu-
mab is unknown. There are only a few reports on ad-
verse systemic effects, such as myocardial infarction,
cerebrovascular accident and hypertension [2,3]. We re-
port a case of abdominal aortic aneurysm rupture after
an intravitreal bevacizumab injection for neovascular
AMD.
Case presentation
A 74-year-old Korean man presented with visual dis-
turbance in his right eye. He had previously been* Correspondence: magicham@hanmail.net
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stated.diagnosed with diabetes and hypertension, which were
controlled by oral medications.
On his initial examination, his best corrected visual
acuity was 20/40 in his right eye and 20/25 in his left
eye. A fundus examination revealed macular elevations
with a subretinal neovascular membrane in his right eye
(Figure 1A). Optical coherence tomography showed sub-
macular elevations with intraretinal edema (Figure 1B)
and a fluorescein angiography showed macular fluores-
cein leakage in his right eye (Figure 1C). He was diag-
nosed with AMD.
We administered an intravitreal bevacizumab (1.25mg)
injection for treatment of the AMD in his right eye. We
used an aseptic technique, including irrigation of the
conjunctival sac with diluted povidone-iodine (Betadine)
solution. Our patient received oral and topical antibi-
otics for three days after the injection. The intravit-
real injection of bevacizmab was to be repeated every
month.
Four days after his third intravitreal bevacizumab in-
jection, he visited our emergency room with decreased
consciousness. On initial physical examination, his blood
pressure was 83/54mmHg with a heart rate of 63 beats
per minute. A contrast-enhanced computed tomography
scan revealed an abdominal aortic aneurysm of 5.8cm intral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Fundus photo, optical coherence tomography, fluorescein angiography and computed topography of patient. (A) A fundus
examination revealed macular elevations with subretinal neovascular membranes. (B) Optical coherence tomography showed submacular
elevations with intraretinal edema. (C) Fluorescein angiography showed macular fluorescein leakage. (D) A contrast-enhanced computed tomography
scan revealed an abdominal aortic aneurysm, 5.8cm in its largest diameter, with ruptured state and bilateral iliac artery aneurysms.
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artery aneurysms (Figure 1D). Although an emergency
abdominal aortic aneurysm repair was performed, our
patient died of uncontrolled bleeding through the rup-
tured wall.
Discussion
AMD is the leading cause of irreversible blindness in
people over the age of 50 in the developed world [4].
VEGF is considered a key player in the development of
abnormal vessels for many pathological conditions, in-
cluding AMD, and the antibodies that could inhibit the
development of active VEGF forms [5,6].
Currently, the most commonly used VEGF antagonists
are ranibizumab (Lucentis; Genentech, San Francisco,
CA, USA) and bevacizumab (Avastin; Genentech, San
Francisco, CA, USA). Ranibizumab has been approved
for the treatment of patients with neovascular AMD by
the US Food and Drug Administration. In contrast to
ranibizumab, bevacizumab was not developed for the
treatment of AMD and consequently has no approval
for such use. But, because of its similar mode of action,
availability and comparatively low costs, bevacizumab is
widely used in the treatment of AMD [7,8].
In the several large randomized controlled trials of
ranibizumab, the adverse systemic safety events that oc-
curred during the study period were prospectively re-
corded, irrespective of their suspected relationships tothe study treatments [9,10]. Systemic events caused by
ranibizumab were rare. With bevacizumab, there are
only a few reports of adverse systemic safety events, such
as myocardial infarctions, cerebrovascular accidents and
hypertension [2,3].
Bakri et al. reported the pharmacokinetics of 0.5mg of
intravitreal ranibizumab (Lucentis) and 1.25mg of intra-
vitreal bevacizumab (Avastin) using the same rabbit
model [11]. After the intravitreal injection, no ranibizu-
mab was detected in the serum but low concentrations
of bevacizumab were detected. A maximum concentra-
tion of 3.3μg/mL was achieved eight days after the intra-
vitreal injection, and the concentration had fallen below
1μg/mL 29 days after the intravitreal injection.
The intravitreal half-life of bevacizumab is estimated
to be 5.6 days [12]. This is longer than that of ranibizu-
mab, which is 3.2 days. So, repeated consecutive intravit-
real injections of bevacizumab are more likely to result
in accumulation than repeated ranibizumab injections.
There are various known predictors for an increased
risk of abdominal aortic aneurysm rupture, such as the
aneurysm size, aneurysm growth rate, smoking, chronic
obstructive pulmonary disease and hypertension [13].
However, an association between chemotherapy and ab-
dominal aortic aneurysm expansion has not yet been
established. Palm et al. [14] reported a case of ruptured
abdominal aortic aneurysm in a patient receiving chemo-
therapy with gemcitabine for pancreatic cancer. They
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vantageous effects on the abdominal aortic aneurysm. The
potential mechanisms may have involved the inhibition of
smooth muscle cell proliferation and collagen and elastin
synthesis. But gemcitabine has different mechanisms from
bevacizumab. Thus, this case is less relevant to ours.
In our patient, it seems reasonable to consider a pos-
sible correlation between intravitreal injection of bevaci-
zumab and rupture of the abdominal aortic aneurysm.
Injecting bevacizumab into the systemic circulation may
have negative effects on hypertension and abdominal
aortic aneurysm. Hypertension and instability of athero-
sclerotic plaque are well-known risk factors of abdom-
inal aortic aneurysm rupture [15]. VEGF stimulates the
synthesis of endothelial nitric oxide synthase and prosta-
cyclin in endothelial cells, and its inhibition is associated
with vasoconstriction that increases hypertension [16].
Also, bevacizumab inhibition of VEGF increases inflam-
mation and atherosclerotic instability, which leads to
plaque ruptures [17]. From our experience with our pa-
tient, we deduce that the two mechanisms could explain
the occurrence of abdominal aortic aneurysm rupture.
Conclusions
An intravitreal injection of bevacizumab in a patient
with an abdominal aortic aneurysm is very rare. This
makes any statistical analysis difficult, and it is unclear
whether an abdominal aortic aneurysm rupture is an ad-
verse effect of the intravitreal bevacizumab injection or
an unrelated natural course of the aneurysm. But an ab-
dominal aortic aneurysm rupture is highly lethal and
there is a possible correlation with intravitreal injection
of bevacizumab. Therefore, we need to consider the risks
of intravitreal bevacizumab injection for patients with
abdominal aortic aneurysms. To the best of our know-
ledge, this is the only case reported that describes large
artery rupture that could be a result of an intravitreal
bevacizumab injection.
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